Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Buy RMD now and get great upside returns in a year or two, page-8
-
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$29.90 |
Change
1.250(4.36%) |
Mkt cap ! $18.94B | |||
| Open | High | Low | Value | Volume |
| $29.38 | $29.90 | $29.28 | $56.93M | 1.920M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2798 | $29.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $29.91 | 9379 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |